GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (FRA:BM8) » Definitions » Short Interest

Biomarin Pharmaceutical (FRA:BM8) Short Interest


View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Biomarin Pharmaceutical's Short Interest

For the Biotechnology subindustry, Biomarin Pharmaceutical's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomarin Pharmaceutical's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Short Interest distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Short Interest falls into.


Biomarin Pharmaceutical (FRA:BM8) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (FRA:BM8) » Definitions » Short Interest
Comparable Companies
BGNE ALNY RPRX SRPT INCY UTHR TECH BNTX ROIV LEGN OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX OCSE:GMAB
Traded in Other Exchanges
BMRN:USA 1BMRN:Italy BM8:Germany B1MR34:Brazil
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
Website
http://www.bmrn.com
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (FRA:BM8) Headlines

No Headlines